These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37817501)

  • 1. Potential use of psilocybin drugs in the treatment of depression.
    Śladowska K; Kawalec P; Brzostek T; Pilc A
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):241-256. PubMed ID: 37817501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing potential of psilocybin for depressive disorders.
    Kozak Z; Johnson MW; Aaronson ST
    Expert Opin Investig Drugs; 2023; 32(10):887-900. PubMed ID: 37869790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of psilocybin: a systematic review.
    van Amsterdam J; van den Brink W
    Expert Opin Drug Saf; 2022 Jun; 21(6):833-840. PubMed ID: 35225143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of psilocybin for treatment-resistant depression].
    Johannesdottir A; Sigurdsson E
    Laeknabladid; 2022 Sep; 108(9):403-410. PubMed ID: 36040772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability.
    Barber G; Nemeroff CB; Siegel S
    Am J Psychiatry; 2022 Dec; 179(12):892-896. PubMed ID: 36453037
    [No Abstract]   [Full Text] [Related]  

  • 12. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
    Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
    Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI
    J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Return of the psychedelics: Psilocybin for treatment resistant depression.
    Patra S
    Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.
    Prouzeau D; Conejero I; Voyvodic PL; Becamel C; Abbar M; Lopez-Castroman J
    Curr Psychiatry Rep; 2022 Oct; 24(10):573-581. PubMed ID: 35953638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.
    Agin-Liebes G; Davis AK
    Curr Top Behav Neurosci; 2022; 56():125-140. PubMed ID: 34811715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.
    Andersen KAA; Carhart-Harris R; Nutt DJ; Erritzoe D
    Acta Psychiatr Scand; 2021 Feb; 143(2):101-118. PubMed ID: 33125716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Registered clinical studies investigating psychedelic drugs for psychiatric disorders.
    Siegel AN; Meshkat S; Benitah K; Lipsitz O; Gill H; Lui LMW; Teopiz KM; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2021 Jul; 139():71-81. PubMed ID: 34048997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.